Morgan Stanley assumed coverage of Organogenesis (ORGO) with an Equal Weight rating and an unchanged price target of $4. Organogenesis has an “attractive” regenerative product, but limited long-term visibility, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORGO: